Kiadis Still Betting On Blood Cancer Immunotherapy Launch This Year
Executive Summary
Kiadis has conducted further analyses of data on its investigational blood cancer therapy ATIR101 and is now hoping to secure EU approval in time for the therapy to be used in the first patients by the end of 2019.
You may also be interested in...
Kiadis Crushed By EMA Rejection Of T-Cell Therapy
The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.
Novartis Wants More Time To Answer EMA’s Zolgensma Questions
Novartis unit AveXis is one of several companies seeking extra time to address questions the European Medicines Agency has regarding their marketing applications. The company says it could get a decision on whether the product should be approved in the EU by year-end.
Kiadis Raises €28m As Cell Therapy Nears Commercialization
The funding comes as the Dutch biotech closes in on a potential conditional approval and closure of its acquisition of CytoSen.